beta-Catenin (C18) Antibody-Delta Biolabs

Product Info
Background	The multifunctional beta-catenin protein was originally identified through its association with the cadherin class of cell adhesion proteins (1&2). It was later found to be an integral part of signal transduction pathways and the best studied is the Wnt/beta-catenin pathway (3). Wnt signaling inhibits the degradation of beta-catenin and as a result beta-catenin becomes transcriptionally active (3-5). The deregulation of Wnt signaling leads to the accumulation of beta-catenin, allowing it to become transcriptionally active for a number of genes. Many of these genes are associated with cancer, such as colorectal cancer and melanomas (3&4).
Origin	beta-catenin (C18) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminal domain of human beta-catenin.
Product Details	Each vial contains 200 �g/ml of affinity purified rabbit IgG, beta-catenin (C18) DB077, in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Competition Studies	A blocking peptide is also available, DB077P, for use in competition studies. Each vial contains 0.100 mg of peptide in 0.5 ml PBS with 0.1% sodium azide and 100 mg BSA.
Form	200 �g/ml rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Immunogen	Synthetic peptide mapping to the carboxy terminal domain of human beta-catenin.
Specificity	beta-catenin (C18) is recommended to detect mouse, rat and human beta-catenin
Use	Western blot anlaysis of beta-catenin expression in A431 whole cell lysates.
Storage	Store this product at 4� C, do not freeze. The product is stable for one year from the date of shipment.
References	1. Hinck L, Nathke IS, Papkoff J, Nelson WJ. 1994. ?-catenin: a common target for the regulation of cell adhesion by Wnt-1 and Src signaling pathways. Trends Biochem Sci. 19(12):538-542. 2. Bullions LC, Levine AJ. 1998. The role of ?-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol. 10(1):81-87. 3. Moon RT, Bowerman B, Boutros M, Perrimon N. 2002. The promise and perils of Wnt signaling through ?-catenin. Science 296(5573):1644-1646. 4. Li H, Pamukcu R, Thompson WJ. 2002. ?-catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther. (6):621-625. 5. Hecht A, Kemler R. 2000. Curbing the nuclear activities of ?-catenin. Control over Wnt target gene expression. EMBO 1(1):24-28.